Bavarian Nordic (OTCMKTS:BVNRY) Short Interest Update

Bavarian Nordic (OTCMKTS:BVNRY) saw a large drop in short interest during the month of July. As of July 15th, there was short interest totaling 1,795 shares, a drop of 31.6% from the June 30th total of 2,625 shares. Based on an average daily volume of 4,660 shares, the days-to-cover ratio is currently 0.4 days. Approximately 0.0% of the shares of the company are sold short.

Bavarian Nordic Trading Up 0.6%

OTCMKTS:BVNRY opened at $9.05 on Friday. Bavarian Nordic has a 12-month low of $8.67 and a 12-month high of $13.00. The stock’s 50 day simple moving average is $9.35 and its 200-day simple moving average is $9.78. The firm has a market cap of $2.15 billion, a P/E ratio of 11.91 and a beta of 1.20.

Bavarian Nordic (OTCMKTS:BVNRY) last issued its quarterly earnings results on Wednesday, May 13th. The company reported $0.01 earnings per share for the quarter. Bavarian Nordic had a return on equity of 9.32% and a net margin of 19.74%.The firm had revenue of $165.70 million during the quarter.

Bavarian Nordic Company Profile

Bavarian Nordic is a fully integrated biotechnology company specializing in the development, manufacture and commercialization of vaccines and immunotherapies. Founded in 1994 and headquartered in Martinsried, Germany, the company combines internal research capabilities with in-house manufacturing to address serious infectious diseases and cancer indications. Bavarian Nordic’s operations encompass preclinical research, clinical development and commercial supply, with a strategic focus on leveraging its proprietary viral vector platforms.

The company’s commercial portfolio includes approved prophylactic vaccines such as Jynneos™ (marketed as Imvamune®/Imvanex®) for the prevention of smallpox and monkeypox in the United States, European Union and Canada; Rabipur® for rabies prevention; and Encepur® against tick-borne encephalitis.